Cellebrite DI (CLBT) – Analysts’ Recent Ratings Updates

A number of research firms have changed their ratings and price targets for Cellebrite DI (NASDAQ: CLBT):

• 8/14/2026 – Cellebrite DI had its price target lowered by Lake Street Capital from $21.00 to $15.00. They now have a “buy” rating on the stock.
• 8/14/2026 – Cellebrite DI had its price target lowered by JPMorgan Chase & Co. from $20.00 to $16.00. They now have an “overweight” rating on the stock.
• 8/14/2026 – Cellebrite DI had its price target lowered by DA Davidson from $22.00 to $15.00. They now have a “buy” rating on the stock.
• 8/14/2026 – Cellebrite DI had its price target lowered by Needham & Company LLC from $15.00 to $12.50. They now have a “buy” rating on the stock.
• 8/13/2026 – Cellebrite DI was downgraded by Weiss Ratings from “hold (c-)” to “sell (d+)”.
• 8/6/2026 – Cellebrite DI had its price target raised by DA Davidson from $20.00 to $22.00. They now have a “buy” rating on the stock.

Insider Activity

In other Cellebrite DI news, CFO David Barter sold 41,734 shares of Cellebrite DI stock in a transaction dated Wednesday, July 8th. The shares were sold at an average price of $16.38, for a total transaction of $683,602.92. Following the completion of the transaction, the chief financial officer owned 334,219 shares in the company, valued at approximately $5,474,507.22. The trade was a 11.10% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Thomas E. Hogan sold 139,713 shares of the company’s stock in a transaction dated Wednesday, August 12th. The shares were sold at an average price of $15.39, for a total transaction of $2,150,183.07. Following the completion of the sale, the chief executive officer directly owned 790,548 shares in the company, valued at $12,166,533.72. This trade represents a 15.02% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 285,276 shares of company stock worth $4,470,330 over the last quarter. Insiders own 5.70% of the company’s stock.

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company’s technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company’s flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.